🇺🇸 LGND — Ligand Pharmaceuticals Incorporated

Salud Compra fuerte
← Volver

Precio actual

313,52 USD

Máx. histórico

322,75

4 días

Split 1603:1000 del 02/11/2022

Caída desde máximo

-2,86%

Rango 52 semanas

175,89 – 326,63

Variación hoy

+2,12%

Cierre anterior

307,02

Rango de hoy

309,46 – 317,76

Volumen hoy

195.564

Peor caída histórica

-93,34%

06/03/2000 → 19/11/2008

Recuperado en 2694 días

Volatilidad anualizada ⓘ

59,76%

Información
Nombre completo
Ligand Pharmaceuticals Incorporated
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Biotechnology
Empleados
47
PER ⓘ
33,04 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
350,92 USD (puede no estar actualizado)
Primera cotización
18/11/1992
Precio actualizado
hace 8 horas
Sobre la empresa

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Dividendos repartidos Total últimos 12 meses: 0,0000 USD · Yield: 0,00%
Fecha de pago Importe por participación
03/04/2007 9,3575 USD
Splits Registrados en el histórico de precios
Fecha Ratio
02/11/2022 1603:1000
19/11/2010 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/12/2024 122,61 123,32 119,50 119,93 -2,26% 3,12% 81.200
02/12/2024 121,99 124,00 119,18 122,70 +1,01% 3,95% 83.400
29/11/2024 123,44 124,34 120,01 121,47 -0,88% 3,51% 72.100
27/11/2024 123,65 125,00 121,06 122,55 -1,43% 3,19% 88.900
26/11/2024 120,62 124,44 119,78 124,33 +3,08% 3,86% 182.800
25/11/2024 119,74 122,63 119,04 120,62 +1,20% 3,00% 153.700
22/11/2024 116,22 120,00 116,22 119,19 +2,27% 3,25% 93.200
21/11/2024 112,80 118,12 112,06 116,55 +4,47% 5,37% 83.400
20/11/2024 111,59 112,00 109,53 111,56 -0,21% 2,21% 133.600
19/11/2024 110,72 112,27 109,78 111,80 +0,12% 2,25% 98.200
18/11/2024 110,87 113,04 109,44 111,67 -0,04% 3,25% 125.900
15/11/2024 116,52 116,52 110,32 111,71 -3,24% 5,32% 107.800
14/11/2024 123,22 125,76 114,39 115,45 -5,43% 9,23% 135.200
13/11/2024 122,00 123,72 120,99 122,08 +1,11% 2,24% 219.100
12/11/2024 123,08 124,46 119,69 120,74 -2,21% 3,88% 120.800
11/11/2024 122,24 124,19 120,83 123,47 +1,83% 2,75% 209.200
08/11/2024 126,27 127,26 116,96 121,25 -6,66% 8,16% 260.600
07/11/2024 118,33 129,90 115,16 129,90 +11,12% 12,46% 271.800
06/11/2024 114,09 116,95 111,72 116,90 +5,19% 4,58% 214.600
05/11/2024 109,57 111,59 108,31 111,13 +0,83% 2,99% 86.400
04/11/2024 109,14 110,63 108,11 110,22 +0,16% 2,31% 99.800
01/11/2024 107,05 110,79 107,05 110,04 +4,11% 3,49% 121.400
31/10/2024 109,56 109,56 105,48 105,70 -3,74% 3,72% 100.400
30/10/2024 114,93 115,10 109,81 109,81 -4,95% 4,60% 63.900
29/10/2024 112,98 115,53 112,98 115,53 +1,90% 2,26% 118.700
28/10/2024 113,26 113,51 110,00 113,38 +1,40% 3,10% 206.900
25/10/2024 111,19 113,37 111,13 111,82 +0,75% 2,01% 122.800
24/10/2024 106,89 111,04 106,32 110,99 +3,84% 4,42% 145.000
23/10/2024 106,29 107,28 104,58 106,89 +0,37% 2,54% 64.200
22/10/2024 106,19 106,51 104,29 106,50 -0,26% 2,09% 68.800